Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company Deals

Chengdu Kanghua Biological Products Inks Five-Year Partnership to Boost Sichuan’s Biotech and Vaccine Industries

Fineline Cube Sep 10, 2024

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...

Company Deals

JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development

Fineline Cube Sep 10, 2024

JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200...

Company Medical Device

Amoy Diagnostics’ AiHuiJie Lung Cancer Companion Diagnostic Receives NMPA Approval

Fineline Cube Sep 10, 2024

Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a biopharmaceutical company based in China, has announced...

Company Drug

AstraZeneca and Daiichi Sankyo’s Dato-DXd Misses Overall Survival Endpoint but Shows Promise in NSCLC Subgroup

Fineline Cube Sep 10, 2024

AstraZeneca (NASDAQ: AZN) and its co-development partner, Japan’s Daiichi Sankyo, have released data from the...

Company Deals

Candel Therapeutics Acquires Bispecific Antibodies and Secures $370 Million in Financing for Autoimmune Drug Development

Fineline Cube Sep 10, 2024

Candel Therapeutics, Inc. (CADL), a U.S.-based biopharmaceutical company, has announced the acquisition of two U.S....

Company Drug

Vcanbio’s Stem Cell Therapy VUM02 Gets NMPA Approval for Systemic Sclerosis Clinical Trial

Fineline Cube Sep 10, 2024

Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), a biotechnology company based in China,...

Company Deals

Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation

Fineline Cube Sep 10, 2024

Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...

Policy / Regulatory

NHC Releases Updated List of Pediatric Drugs for Research and Development Incentives

Fineline Cube Sep 10, 2024

The National Health Commission (NHC) has issued a notification regarding the fifth batch of pediatric...

Company Drug

Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial

Fineline Cube Sep 10, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Drug Policy / Regulatory

China’s CDE Issues Draft Guidelines for Biosimilar Pharmaceutical Similarity Research

Fineline Cube Sep 10, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...

Company Deals R&D

Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation

Fineline Cube Sep 9, 2024

Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...

Policy / Regulatory

China’s 2024 Negative List Eases Restrictions on Foreign Investment in TCM and Biotechnology

Fineline Cube Sep 9, 2024

The National Development and Reform Commission (NDRC) of China has announced the release of the...

Policy / Regulatory

China’s NMPA Proposes Inclusion of Cochlear Implants in Volume-Based Procurement Plans

Fineline Cube Sep 9, 2024

The National Medical Products Administration (NMPA) has disclosed plans to expand the scope of its...

Company Deals Medical Device

Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs

Fineline Cube Sep 9, 2024

Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell...

Company Drug

Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study

Fineline Cube Sep 9, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Policy / Regulatory

China’s NHSA Proposes New Guidelines to Enhance Oversight of Medical Insurance Funds

Fineline Cube Sep 9, 2024

The National Healthcare Security Administration (NHSA) has unveiled a draft of the “Guiding Opinions on...

Company Deals

Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership

Fineline Cube Sep 9, 2024

Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray...

Policy / Regulatory

China Opens Doors to Foreign Biotech and Wholly-Owned Hospitals in Healthcare Sector Expansion

Fineline Cube Sep 9, 2024

China’s Ministry of Commerce, National Health Commission, and National Medical Products Administration (NMPA) have jointly...

Company

Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce

Fineline Cube Sep 9, 2024

Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...

Policy / Regulatory

Guangzhou Health Commission Unveils Ten Measures to Boost Innovative Pharma and Medical Device Development

Fineline Cube Sep 9, 2024

On September 5, 2024, the Guangzhou Health Commission issued the “Guangzhou Health Commission’s Ten Measures...

Posts pagination

1 … 332 333 334 … 698

Recent updates

  • Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
  • TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
  • Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
  • Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
  • Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.